Patrick C. Ma, MD

The world's tallest church is about to get its crown. On June 10, 2026, exactly 100 years after Antoni Gaudí's death, the Sagrada Família will inaugurate the four-armed cross atop the Tower of Jesus Christ.

One of the most promising developments in cancer treatment- @NEJM @OncoAlert

Still a big Gap for lung cancer patients

🫁 Long-Term Survival in De Novo Metastatic Cancer. SEER data comparing 1976 vs 2015 showed 5-year OS improved from 10.6% to 23.6% in de novo metastatic cancer. Largest gains: • Breast: 12.6% → 34.2% • Ovarian: 14.4% → 32.5% • Colorectal: 3.7% → 15.0% Minimal progress in pancreatic cancer and SCLC. 📖 @JCOOP_ASCO DOI 👉🏻 doi.org/10.1200/OP-25-… #CánCare #oncology #sclc #metastaticcancer #lcsm

🧬 MARIPOSA adds a new dimension to the EGFR-mutated NSCLC story: resistance biology. This new analysis suggests that first-line amivantamab + lazertinib may do more than improve PFS and OS versus osimertinib. It may actually change the resistance landscape patients develop over time. Key findings from the ctDNA resistance analysis: 📉 MET amplification reduced ~4-fold 📉 Secondary EGFR resistance mutations reduced ~5-fold 🧬 Lower resistance complexity and mutational heterogeneity ⏳ Longer second-line PFS after progression 📈 Median 2L PFS: 8.4 vs 5.3 months vs osimertinib One of the most important concepts here is that first-line therapy may shape what happens after progression, not just before it. Patients treated with amivantamab + lazertinib appeared less likely to develop common EGFR/MET-driven resistance pathways such as: ▪️ MET amplification ▪️ EGFR C797S ▪️ EGFR L718X ▪️ EGFR G724X And patients with “unknown” resistance mechanisms had better second-line outcomes than those with known resistant alterations. The implication is important for thoracic oncology: 👉 The best first-line therapy may not simply delay progression. 👉 It may preserve future treatment sensitivity and reduce resistance complexity. MARIPOSA continues to evolve from a positive efficacy trial into a study about long-term disease biology in EGFR-mutated NSCLC. oncodaily.com/oncolibrary/lu… @cbcbc1971 @nicogirardcurie @DrSanjayPopat @APassaroMD @cbaldotto @BenjaminBesseMD @DavidRSpigel #MARIPOSA #Amivantamab #Lazertinib #Osimertinib #EGFR #NSCLC #LungCancer #ThoracicOncology #TargetedTherapy #ctDNA #METAmplification #EGFRTKI #OncoDaily #OncoDailyLung

Bravo.👍👏👏👏🎊🎊🎊🥳🥳🥳💯

More data presented by @peters_solange debunking the concept that time of day of Immunotherapy administration determines outcomes — 👉🏽what really determines #lungcancer outcomes is #access to the right treatment without delays, not the time of day. #healthequity 👇🏽

🎉First, congrats to @bherzbergmd for being a co-author in the influential @NEJM paper on daroxonrasib! ⭐️Second, please bookmark this thread! Eloquently highlights key tensions in oncology. 💊IMO, we need more trials looking at new sequencing strategies (novel combos upfront, fixed duration intensification, dynamic and conditional trials adapted to longitudinal genomic and epigenomic assessments) along with a more nimble regulatory infrastructure. @lcsmchat @OncoAlert @OncogeneCancer @Lung_Cancers @LungCancerRx @YoungLungCancer @MedwatchKate

Wow. Thanks for the info!

👏A thought-provoking and genuinely paradigm-challenging review @jonas_willmann Metastatic NSCLC progression is not always a single event — it can be a collection of different lesion-specific evolutionary paths. Some metastases remain controlled. Others develop resistance. Some progress rapidly while others stay indolent. This JCO review introduces the concept of “metastatic trajectories”: the spatiotemporal evolution of individual lesions across organs and over time. The key message? 👉 We may need to move beyond treating patients as having one uniform disease state. Instead, integrating: 🔹 lesion-level behavior 🔹 resistance mechanisms 🔹 ctDNA 🔹 radiomics 🔹 local ablative therapies could enable adaptive, biology-informed treatment strategies. An important conceptual step toward truly dynamic precision oncology in NSCLC. @OncoAlert @MedwatchKate @MedicalwatchHQ @OncoReporte @LungSummit

Bravo 👏 👏 👏

What a day it has been!!! @AaronNewmanLab and I started this journey years ago back when we were both junior faculty. A difficult question — Can we perform liquid biopsy of the tumor microenvironment? Spoiler alert. We finally did it! In @Nature & on @CNN today w/ @jaketapper!!

We've known how important the tumor microenvironment is for cancer progression and treatment, but we never had a non-invasive blood test to assess it. Today, as reported @nature, one has been discovered nature.com/articles/s4158…

These women will be the first to tell you .. young lung cancer is real. @LUNGevity #cancer #ylci #lungcancer

We are hiring .... dynamic and motivated faculty candidates for our Hematology/Oncology Section at LSU HSC. Be part of us as team, and part of our effort as builder, to write history for Louisiana and Gulf South in our unwavering drive to attain NCI-Designation for LSU LCMC Health Cancer Center! careers.lsuhsc.edu/jobs/assistant…

A new profile for a new chapter..... at NOLA and LSU LCMC Health Cancer Center, New Orleans 🥳

The May issue of @CD_AACR features the cover article by Dave Tuveson & colleagues @CSHL on the bi-directional crosstalk between sympathetic nerves and fibroblasts within the precancer ecosystem of #PancreaticCancer. aacrjournals.org/cancerdiscover… Editorial aacrjournals.org/cancerdiscover…

🫁 Lung cancer is no longer just about treating disease, it’s about intercepting its evolution! aacrjournals.org/cancerdiscover… This AACR roadmap lays out the shift: ▪️ From late-stage care → early detection & prevention ▪️ From static biology → dynamic tumor evolution ▪️ From single targets → multi-omic integration ▪️ From relapse treatment → MRD-driven intervention The future? Anticipate. Intercept. Adapt. @OncoAlert @OncoReporte @myESMO @_SEOM @LungCancerRx @Lung_Cancers

Your COVID mRNA vaccine may have accidentally helped fight cancer. MD Anderson studied 884 lung cancer patients on immunotherapy. 180 of them got a COVID mRNA vaccine within 100 days of starting treatment. Results (AACR 2026): - Vaccinated group: 37.3 months median survival - Unvaccinated group: 20.6 months - Nearly doubled. The mechanism: mRNA acts like a siren for your immune system. It floods the body with type 1 interferon and upregulates PD-L1, the exact protein that checkpoint drugs target. The vaccine didn't fight COVID here. It supercharged the cancer treatment. This wasn't planned. It was discovered by accident in retrospective data. But 884 patients is not a small number.

Terrific editorial on EGFR’s poor sibling- or lung cancer’s “ugly” duckling: ErbB2 I will give you a Carbone copy so y’all could see what beautiful swan(s) have we raised with suddenly multiple TKI and ADC options available for our pts w ErbB2 mutated NSCLC! But we should not stop here- lets give these swans wings in the coming years! @EGFRResisters #lcsm